Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
DURHAM, N.C. and SEOUL, South Korea, Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a...
Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025
Studies reveal how the Lunit SCOPE ® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading...
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered...
Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions...
Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology
Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit...